The Motley Fool

2 great growth stocks I’d buy right now

I have been a big fan of Scapa Group (LSE: SCPA) for a long time now.

First things first, I am hugely impressed at the rate at which its long-running self help strategy continues to bolster margins, achieved through a combination of contract execution and rigorous cost-cutting. At its Healthcare division, margins rose 1.9% between April and September, to 16.1% while, at Industrial, margins improved 2.2% to 11.5%.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

Secondly, I like Scapa’s broad geographic footprint which provides terrific protection against macroeconomic turbulence in one or two regions.

And thirdly, I am encouraged by the tape manufacturer’s terrific progress in the defensive healthcare sector. Sales at Scapa’s Healthcare unit leapt 7.9% during the first fiscal half, to £57.7m, and it signed contracts with three major OEMs in the period.

Stuck on you

Now Scapa has a great record of doling out double-digit earnings growth, the business having seen the bottom line swell at a compound annual growth rate of 21.9% over the past five years. And City analysts believe there’s much more of where that came from.

For the year to March 2018, forecasts point to a 16% profits improvement and, in fiscal 2019, another 11% advance is predicted.

Meanwhile, expectations of extra heady earnings growth is expected to keep Scapa’s ultra-progressive dividend policy going. The Manchester firm lifted the dividend 14.3% in the last year to 2p per share, and additional meaty increases — to 2.3p and 2.6p in fiscal 2018 and 2019 respectively — are currently being anticipated.

These payouts yield 0.5% and 0.6% respectively, but such low readings would not discourage me given the possibility of Scapa becoming a lucrative income generator in the years ahead.

In my opinion Scapa is a top quality growth stock fully worth a premium P/E ratio of 25.5 times.

Flying high

I also like the investment outlook for Wizz Air (LSE: WIZZ).

The Hungarian business is a major player in the low-cost travel market, a segment that continues to grow at a stratospheric rate. And to cotton onto this rosy backdrop Wizz Air, like many of its rivals, is rapidly expanding.

Having snapped up two slots at London Luton from the collapsed Monarch Airlines in November, it announced it would station an extra two planes at the airport in a move that would bolster its capacity at the base by 18%, to 7.1m slots, in 2018. Wizz Air has big plans for its British base and it also announced three new routes (to Keflavik, Bari and Athens) from there just last week.

So City analysts are expecting earnings at the FTSE 250 flyer to rise 25% in the year to March 2018, and to increase 18% in the following period.

And these forecasts make Wizz Air a brilliant value pick. A forward P/E ratio of 17.8 times may not appear that compelling, although a corresponding PEG multiple of 0.7 really is.

Considering its exciting growth strategy and its exposure to the lucrative emerging markets of Central and Eastern Europe, I reckon Wizz Air is a steal at current prices.

Start 2018 with a bang with this great growth stock

But Wizz Air and Scapa are just a couple of the London-listed heroes you can buy today and live off in the years to come.

Indeed, the Motley Fool's army of analysts has toiled to write this special Fool report which picks out a brilliant FTSE 250 stock that has already delivered stunning shareholder returns, and whose sales are expected to balloon in the next few years.

Click here to enjoy this exclusive wealth report. Our A Top Growth Share investment guide is 100% free and comes with no obligation, so why not check it out?

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.